In the last 23 years, we’ve completed 90 clinical research studies. We’ve seen significant progress in the treatments of the diseases we study, and we’re currently engaged in the studies that will continue to move us closer to finding cures. There are no costs to participate in our studies or for study-related procedures, and often compensation is available for time and travel. For more information on any of the studies listed below, please call us at 941-708-0005.
Trailblazer-ALZ Alzheimer’s Study
This study will look at the effects of 2 investigational drugs. The study will examine if the investigational drugs, either alone or used together, may help to slow or stop memory loss in people with early stages of Alzheimer’s disease.
You may be able to take part in this study if you:
are 60-85 years of age
have had memory loss for 6 months or more that has become gradually worse over time
have a family member or close friend who is with you at least 10 hours per week and can attend study appointments with you.
Tauriel Alzheimer’s Study
The TAURIEL Study will look at an investigational medication for people with Alzheimer’s disease. The study will help determine how safe the investigational medication is and whether or not it works in affecting Alzheimer’s disease.
The TAURIEL Study might be right for you if you:
are 50 to 80 years of age
have mild Alzheimer’s disease or problems with memory
have somebody who can be a reliable study partner or caregiver and who can come to some study visits with you and answer questions about your health
Early Alzheimer’s Study
This medical study is for people people who are experiencing increasing problems with their memory that may be early symptoms of Alzheimer’s disease. This study will evaluate the effectiveness of an investigational product (study drug). The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. Potential patients for this study are:
·Aged 50 to 80 years old
·Have early symptoms of Alzheimer’s Disease
Early Alzheimer’s Combined Treatment Study
This clinical research trial is enrolling men and women who may have evidence of early stage Alzheimer’s disease. The clinical trial is evaluating whether a combined treatment slows down early stage Alzheimer’s disease. Qualified participants must:
· Be 55 to 79 years old
· Have mild memory impairment
· Have a spouse, close person or relative who spends a lot of time with the participant to accompany the participant at study visits
· Be in good general health
The purpose of this medical study is to collect biological samples from subjects with Parkinson’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Parkinson’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Parkinson’s disease. Your samples will be kept indefinitely by the sponsor. The sponsor may analyze your sample as part of other research activities.
The objective of this study is to collect serial 6 monthly (every 6 months) CSF and blood samples from individuals that have been diagnosed with MS or Clinically Isolated Syndrome. The CSF and blood samples will be stored for future research. This future research will be used to delineate genetic and other markers for the disease, enhance the understanding of treatment response and side effects, and develop new targets for future drug development. To be eligible for this study, individuals must:
·Be 18 years or older
·Have a diagnosis of MS or Clinically Isolated Syndrome
Alzheimer’s Combination Study
This medical study is examining whether an investigational medication, when given with two standard medications for Alzheimer’s disease, has an effect on mental abilities impaired by the disease. We are looking for individuals who:
• Are aged 50 to 85 years
• Have had Alzheimer’s disease for at least 1 year
• Are currently receiving treatment with donepezil and memantine / Namenda XR®
or the combination product, Namzaric™
• Have a friend or relative willing to be their study partner throughout the study
Multiple Sclerosis Spasticity Study
The purpose of this study is to assess a medication, arbaclofen extended-release tablets (AERT), for treatment of spasticity in patients with multiple sclerosis (MS). Individuals may be eligible for this study if they are:
·Aged 18 to 65
·Diagnosed with MS